Clinical Trial Update: Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Afabicin for bone or joint infections caused by Staphylococcus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis
• Septic Arthritis

Drugs mentioned

• Afabicin (afabicin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Bone or Joint Infection | Phase 2 | Status: TERMINATED